FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Aeolus Pharmaceuticals, Inc. Stock AnalysisComprehensive stock analysis for Aeolus Pharmaceuticals, Inc. (AOLS) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAOLS
AOLS
Aeolus Pharmaceuticals, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
AOLS
Home🔹Stocks🔹Aeolus Pharmaceuticals, Inc.

Aeolus Pharmaceuticals, Inc.

AOLS•OTC

Aeolus Pharmaceuticals, Inc.

AOLS•OTC
Market cap
$15.21K
Sentiment

Your view on AOLS

Mkt Cap
$15.21K
Sentiment
Your view
AOLS
Aeolus Pharmaceuticals, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
AOLS
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Aeolus Pharmaceuticals, Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Christopher Stanley
Headquarters
26361 Crown Valley Parkway, Mission Viejo, CA, US
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Christopher Stanley
Headquarters
26361 Crown Valley Parkway, Mission Viejo, CA, US
Description

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News